Enanta Pharmaceuticals | ENTA - Beneficio Bruto En Ventas

Precio De Mercado
12.69
Cambio Diario
0.18 1.44%
Mensual
-13.97%
Anual
104.68%
Q1 Expectativa
12.13




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Amgen USD 6.48B 307M 2025-09
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.65B 34.6M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Immunic 0 0 2025-03
Incyte USD 1.39B 118.68M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 16.6B 118M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12